PNEUMONIA TESTING MARKET ANALYSIS

Pneumonia is a lung infection caused by bacteria, viruses or fungi, primarily affecting the small sir sacs known as alveoli. The most common bacterial type that causes pneumonia is Streptococcus pneumoniae. The symptoms for pneumonia include, fever, chills, cough, shortness of breath and fatigue. To detect whether, a person has pneumonia are blood tests, chest X-ray, pulse oximetry, and Sputum test. Further, if the patients is older than age 65, additional tests are included for detection of pneumonia. For instance, CT scan, Pleural fluid culture.

The blood tests are used to confirm an infection and to try to identify the type of organism causing the infection, but however precise identification is not always possible through the blood tests. Further, the chest X-ray also helps the doctor to diagnose pneumonia and determine the extent and location of the infection. The chest X-ray can also detect the kind of germ is causing pneumonia. The pulse oximetry test is performed to measure the oxygen level in the blood, as Pneumonia can prevents lungs from moving enough oxygen into the bloodstream. Besides all these test the sputum test is used to analyses or pinpoint the cause of the infection with the sample of fluid from lungs, which is taken after deep cough.

Furthermore, if the pneumonia isn’t clearing as quickly as expected the doctors recommend a chest CT scan to obtain a more detailed image of the lungs. Moreover, if the patients shows serious symptoms or health conditions pleural fluid culture test is carried out where a fluid sample is taken by putting a needle between the ribs from the pleural area to analyze the type of infection.

Pneumonia Testing Market Dynamics

The recent advancements in pneumonia testing systems, such as the development of enhanced nucleic acid detection tests and advancement in POC tests is the major factor that contributes toward the growth of the pneumonia testing market size. As POC tests offers multiple benefits offered such as, ease of use, and rapid results. For instance, The urinary antigen is an extremely-effective rapid test that allows targeted therapy foe legionnaire at the point-of-care itself.

Further, increasing adoption of molecular diagnostic test in the developing economy is anticipated to provide lucrative opportunities to the pneumonia testing market. Due to increased application of biomarkers in molecular diagnostic, due to advantages of biomarkers such as aiding in early detection of specific diseases, supports the molecular diagnostics test for pneumonia testing market.

Initially, in the traditional method, cultures are used to detect pneumonia causative organisms. This is a time-consuming process with a higher error rate when compared to rapid diagnostics. In a few cases such as legionella, culture identification is not readily available and this increases the mortality rate of pneumonia cases caused by it.

Pneumonia Testing Market - Regional Insights

North America accounted for the largest share in the pneumonia testing market, followed by Europe market in 2016. This is attributed to growing popularity for POC tests within the healthcare sector. Further, the ongoing research and development activities are also on rise for the development of more advanced PCR-based technologies, which could be used for faster results.

Further, pneumonia testing market in accounts second largest share in Europe region, primarily because of their robust, well-developed healthcare infrastructure and a greater awareness of a geriatric population likely to develop such health issues.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region, to maximize on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, with lower cost operational efficiencies. Increasing government investment in research and development is also expected to foster growth of Pneumonia Testing in Asia Pacific region.

Rising product launch and product approval is expected to drive the market growth. For instance, in November 2018, bioMérieux received 510(k) clearance from the Food and Drug Administration (FDA) for BIOFIRE FILMARRAY Pneumonia Panel which enables diagnosis of lower respiratory tract infections. Similarly, in April 2018, Curetis N.V., received de novo clearance from the U.S. Food and Drug Administration for marketing of  Unyvero System and Lower Respiratory Tract Infection (LRT) Application Cartridge an automated molecular diagnostic test in the U.S. The system offers rapid infectious disease testing for detection of Legionella pneumoniae microorganism.  

Major players are focused on collaborations and mergers, to enter the pneumonia testing market. For instance, in April 2017, Abbott acquired Alere, which dominated POC testing for pneumonia testing market with its BinaxNOW Streptococcus pneumoniae antigen card for bacterial pneumonia and BinaxNOW RSV Card for viral pneumonia.

Pneumonia Testing Market – Regional Insights

North America accounted for the largest share in the pneumonia testing market, followed by Europe market. This is attributed to growing popularity for POC tests within the healthcare sector. Further, the ongoing research and development activities are also on rise for the development of more advanced PCR-based technologies, which could be used for faster results.

Further, pneumonia testing market in accounts second largest share in Europe region, primarily because of their robust, well-developed healthcare infrastructure and a greater awareness of a geriatric population likely to develop such health issues.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region, to maximize on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, with lower cost operational efficiencies. Increasing government investment in research and development is also expected to foster growth of Pneumonia Testing in Asia Pacific region.

Pneumonia Testing Market - Taxonomy:

By Product Type:

• Analyzers
  • Point-Of-Care (POC)
  • Non-POC
• Consumables

By Technology:

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunofluorescence
• Western Blot
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Molecular Diagnostics
• Others

By End User

• Hospitals
• Diagnostic Centers
• Homecare Settings
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Key players in the pneumonia testing market:

Some of the key players operating in the pneumonia testing market includes Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.